E2 Raises $80M to Advance Pulmonary Embolism Treatment
This image was generated by AI and may not depict real events.
E2, a medical technology company, has raised $80 million in Series C funding to advance its pulmonary embolism treatment platform. The funding will accelerate commercialization of the Hēlo Thrombectomy Platform, which provides a more efficient and precise alternative to traditional treatment options.
E2, a medical technology company, has raised $80 million in Series C funding. The funding was co-led by Gilde Healthcare and Norwest. E2's Hēlo Thrombectomy Platform treats pulmonary embolism, a leading cause of cardiovascular death. The platform provides a more efficient and precise alternative to traditional treatment options. It integrates aspiration with mechanical clot disruption, allowing physicians to complete procedures in a single pass. The funding will accelerate commercialization of the platform in North America and internationally.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.